Introduction
The vertebrate rel/nf-kb gene family of transcription factors is comprised of c-rel, relA, relB, nf-kb1, nf-kb2, and the c-rel-derived viral oncogene v-rel. All encode proteins with highly conserved N-terminal Rel homology domains (RHDs) that enable formation of homoor heterodimers, nuclear localization and binding to consensus NF-kB DNA sites (reviewed in Karin and Ben-Neriah, 2000) . In contrast, their divergent C-terminal domains contribute unique properties. The C-termini of the vertebrate p105/NF-kB1, and p100/ NF-kB2 factors contain inhibitory ankyrin repeats similar to those found in the IkB family of Rel/NF-kB protein regulators. The C-termini of c-Rel, RelA, RelB, and v-Rel function as transcription activation domains (TADs). Under normal conditions and in most cells, Rel/NF-kB factors exist as inactive dimeric complexes sequestered in the cytoplasm by members of the IkB family of inhibitory factors. Cell stimulation triggers the NF-kB signaling cascade via activation of the IKK kinase complex (reviewed in Karin and Ben-Neriah, 2000) . The consequent phosphorylation and ubiquitinmediated degradation of IkB allows nuclear accumulation of active NF-kB dimeric complexes and the activation of specific programs of NF-kB-mediated gene transcription.
Gene activation by vertebrate Rel/NF-kB factors is key for normal immune and inflammatory responses and also modulates fundamental cellular processes including cell proliferation, apoptosis, cell adhesion, and angiogenesis (reviewed in Karin and Ben-Neriah, 2000; Karin et al., 2002; Kucharczak et al., in press ). Not surprisingly, the last few years have seen a virtual explosion in the number of tumors identified with chromosomal amplification, overexpression, or rearrangement of rel/nf-kb genes and/or constitutively high levels of nuclear NF-kB (reviewed in Rayet and Ge´linas, 1999; Gilmore et al., 2002; Karin et al., 2002) . For instance, c-rel is amplified in diffuse large B cell lymphoma, primary mediastinal (thymic) B-cell lymphoma, follicular large cell lymphoma, and in neoplastic cells of classical Hodgkin's disease (Lu et al., 1991; Houldsworth et al., 1996; Joos et al., 1996 Joos et al., , 2002 Barth et al., 1998 Barth et al., , 2003 Rao et al., 1998; Wessendorf et al., 2003) . In some instances, gene amplification correlates with accumulation of nuclear c-Rel protein . Constitutive activation of the NF-kB signaling pathway is also observed in a growing number of leukemias and lymphomas including malignant ReedSternberg cells of Hodgkin's lymphoma, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, chronic myelogenous leukemia, adult T-cell leukemia, and several solid cancers (Bargou et al., 1997; Kordes et al., 2000; Davis et al., 2001; Hinz et al., 2001 ; and reviewed in Rayet and Ge´linas, 1999; Gilmore et al., 2002) . This most commonly results from persistent activation of the IKK kinase complex, but in some instances is due to mutations that functionally inactivate the IkB subunits (Bargou et al., 1996 (Bargou et al., , 1997 Krappmann et al., 1999; Davis et al., 2001; Hinz et al., 2001) . A common consequence of these alterations in human tumors is the constitutive activation of nuclear NF-kB activity, which is often coupled with increased cell resistance to apoptosis. Indeed, suppression of NF-kB activity sensitizes tumor cells to chemotherapeutic agents and causes them to undergo demise through programmed cell death (for example, Bargou et al., 1997; Davis et al., 2001 , and reviewed in Sonenshein, 1997; Barkett and Gilmore, 1999; Baldwin, 2001; Kucharczak et al., in press ). This suggests an active role for NF-kB in the induction and/or maintenance of the malignant state.
To date, virtually all members of the vertebrate Rel/ NF-kB gene family have been implicated in human cancers with the exception of RelB. However, the mechanisms by which they contribute to tumorigenesis have yet to be clarified. The viral oncoprotein v-Rel, a derivative of c-Rel, is the only acutely oncogenic member of this family as it efficiently transforms primary chicken lymphoid cells to form colonies in soft agar and causes aggressive and fatal leukemia/lymphomas in chickens and transgenic mice (reviewed in Gilmore et al., 1996) . The latency of tumor development in young chickens is generally 7-10 days with 100% penetrance. In contrast to v-rel, its avian cellular homolog c-rel is weakly transforming in chicken lymphoid cells and embryo fibroblasts Kralova et al., 1994; Nehyba et al., 1994; Zurovec et al., 1998) . In addition, lymphoid tumors arising in young chickens following retroviral-mediated delivery of chicken c-rel (cc-rel) invariably revealed selection for C-terminal truncation of the protein . Recently, overexpression of the human c-rel gene was shown to promote the growth of primary lymphoid cells in liquid culture but it failed to induce colony formation in soft agar unless cells were preselected for established growth in liquid culture or coexpressed cell death inhibitor Bcl-2 (Gilmore et al., 2001) . The recent demonstration that MMTV-c-rel transgenic mice develop late-onset mammary carcinomas also raised the possibility that manifestation of a weak oncogenic potential by c-rel perhaps requires additional genetic alterations (Romieu-Mourez et al., 2003) .
In this report, we directly assessed the oncogenic potential of mammalian cellular Rel/NF-kB factors in lymphocytes both in vitro and in vivo. We show that overexpression of wild-type mammalian c-rel genes alone is sufficient to transform primary spleen cells in soft agar assays in vitro and induce fatal tumors in chickens, whereas relA, relB, p50/nf-kb1, p52/nf-kb2, and ikkb did not. Replacement of the RelA transactivation domain with that of v-Rel sufficed to convert RelA into a potent oncogenic factor both in vitro and in vivo. Likewise, mutual exchanges between the mouse and human c-Rel proteins increased the oncogenic phenotype of human c-rel and reduced that of mouse c-rel. These studies demonstrate significant differences in the intrinsic oncogenic activities of individual cellular Rel/ NF-kB factors and reveal that some of these differences originate from their highly divergent C-terminal transactivation domains (TADs).
Results

Mammalian c-Rel and RelA proteins show significantly different transforming potentials in primary lymphoid cells
Since v-Rel efficiently transforms primary chicken lymphoid cells, we sought to determine the transforming activity of other NF-kB family members by colony formation in efficient soft agar assays (Rayet et al., 2003) . The significant degree of sequence divergence among the C-terminal domains of c-Rel proteins from different species (24-59% amino-acid identity) led us to compare the transforming activities of the c-rel genes from chicken, mouse, and human origins, as well as those of the mouse and human relA genes. In light of its implication in many human tumors, a retroviral construct was used to express a constitutively active mutant of the IkB kinase IKKb to mimic persistent activation of the NF-kB signaling pathway (IKKb SS-EE ; Geleziunas et al., 1998) . v-rel served as a positive control.
v-rel yielded about 200 colonies of transformed primary cells per transfection (Figure 1a) . Importantly, overexpression of the chicken, mouse, and human c-rel genes also induced colony formation, albeit less efficiently than v-rel (cc-rel, mc-rel, hc-rel; Figure 1a) . Interestingly, the chicken and mouse c-rel genes consistently displayed significantly higher transformation efficiencies than human c-rel, although all were expressed efficiently ( Figure 1b, lanes 3-5) . Despite its weaker transforming activity, some assays with human c-rel produced up to 25 transformed colonies per reaction (hc-rel; Figure 1a ). Another important finding was that multiple assays with the human or mouse relA genes, or a constitutively active form of IKKb (IKKb SS-EE ), reproducibly failed to produce any colony in soft agar ( Figure 1a ; data not shown). Coexpression of hRelA with cell death inhibitor Bcl-xL also failed to transform cells (data not shown). This is contrary to weakly transforming mutants of v-Rel and c-Rel for whom coexpression of cell death suppressors of the Bcl-2 family rescued their transforming phenotype Gilmore et al., 2001; Rayet et al., 2003) . RelA and IKKb SS-EE also failed to promote the growth of primary lymphoid cells in liquid culture assays that were recently described to be significantly more permissive indicators of cell transformation (data not shown; Gilmore et al., 2001) . The unique transforming activities of c-Rel proteins as compared with RelA did not appear to result from differences in expression levels, as shown by Western blots (Figure 1b , lanes 3-5 and 8; data not shown). Overall, these data demonstrate that similar to v-rel, overexpression of mammalian c-rel genes can transform primary lymphoid cells to induce colony formation in stringent soft agar assays for malignant cell transformation, whereas overexpression of relA or IKKb SS-EE failed to do so. In conjunction with the significantly different transformation efficiencies that we observed between the c-rel genes from different species, these results point to fundamental differences between the intrinsic oncogenic properties of mammalian c-Rel and RelA proteins in lymphocytes that perhaps derive from their divergent TADs.
Mutation or C-terminal truncation is not a prerequisite for lymphoid cell transformation by mammalian c-Rel proteins Similar to immortalized v-Rel-transformed cells, colonies that arose in soft agar with mammalian c-Rel proteins could be isolated and expanded indefinitely in liquid culture as immortalized cell lines. Immunoblotting of transformed cell clones confirmed production of the expected v-Rel, chicken, mouse, human c-Rel proteins without apparent change in size or electrophoretic mobility (Figure 1c) . However, since the highly oncogenic v-Rel factor is a truncated and mutated version of its less oncogenic cellular homolog c-Rel, we went on to analyse proviral DNA from individual lymphoid cell clones transformed by mammalian c-rel genes for possible small deletions or point mutations by RT-PCR and DNA sequence analysis. Experiments revealed no rel gene mutation following transformation by v-rel, cc-rel, or the hc-rel genes, and only two out of 10 clones transformed by mc-rel had a point mutation that resulted in premature termination of the protein (data not shown). Altogether, these analyses indicate that overexpression of wild-type mammalian c-rel genes is sufficient to both immortalize and transform primary lymphoid cells in vitro and that mutation or C-terminal truncation is not a necessary prerequisite.
Spleen cells overexpressing mammalian c-Rel proteins are tumorigenic in vivo
To further assess the oncogenic potential of mammalian c-rel genes, clones of primary spleen cells transformed by mouse or human c-rel were assayed for tumor formation by intraperitoneal transplantation into 5-dayold chickens. As shown in Figure 2 , all animals injected with control v-rel-transformed cells succumbed rapidly, within 6-9 days postinoculation. All animals injected with mouse c-rel-transformed cells also developed lethal tumors, albeit with slightly delayed latency compared to v-rel. Out of six chickens injected with cells transformed by human c-rel, two died between days 10 and 15 postinoculation while the remaining animals did not show tumor development during the 1-month course of the experiment. Importantly, all animals that succumbed, including those injected with cells transformed by human c-rel, had developed visible tumor nodules on their spleen and liver at the time of autopsy. These results demonstrate that overexpression of wild-type mammalian c-Rel proteins can lead to a fully malignant phenotype including the capacity to induce lymphoid tumors in vivo. Furthermore, the overall tumorigenicity in terms of the number of animals affected and the latency of tumor development generally paralleled their transforming activity in vitro. These results further highlight important differences between the oncogenic potential of these factors.
Substitution with the transactivation domain of v-Rel is sufficient to convert human RelA into a potent oncogenic factor in vitro and in vivo
We went on to investigate the molecular basis for the significantly different transforming potentials of v-rel and its mammalian homologs c-rel and relA. On the one hand, the N-terminal RHD of the highly oncogenic vRel is more closely related to those of the mouse or human c-Rel proteins (77-80% amino-acid identity) than to that of RelA (61% identity). It is thus conceivable that the greater similarity between the DNA-binding and dimerization domains of c-Rel proteins from different species may allow them to preferentially bind to subsets of cellular genes that RelA may not bind to with high affinity. On the other hand, the C-terminal TADs of mouse and human c-Rel are 59% identical to one another but are highly divergent from those of mammalian RelA factors (9-11% aminoacid identity). This significant degree of sequence variation in their TADs could perhaps be responsible for their different transforming potentials.
To address this issue, we generated hybrid proteins between v-Rel, mouse c-Rel, human c-Rel, and human RelA (Figure 3a ). Transient transfection assays in 293T cells verified that all hybrid proteins were appropriately expressed and that they were competent for binding to a consensus IL6 promoter-derived NF-kB DNA site in gel retardation and supershift assays (Figure 3b , c; data not shown). Since the transfection efficiency of primary chicken spleen cells was too low to assess the transcriptional activity of these proteins, transient assays on an IL6-kB luciferase reporter were conducted in Tera-2 cells, which contain very low levels of endogenous NFkB activity and are commonly used to assess the transcriptional activity of v-Rel and c-Rel without interference with endogenous NF-kB factors. These assays confirmed the greater transactivation potentials of the cellular RelA and c-Rel factors compared to v-Rel ( Figure 3d ). This is consistent with prior work showing that v-Rel is generally a weaker transcriptional activator on most NF-kB site reporter constructs than its homologs c-Rel and RelA (Ballard et al., 1990; Inoue et al., 1991; Richardson and Gilmore, 1991; McDonnell et al., 1992; Walker et al., 1992; Schatzle et al., 1995; Nehyba et al., 1997) . Hybrid proteins containing the RHD of RelA were more adept at activating expression of IL6 kB-luc than those containing the RHD of v-Rel, mc-Rel, or hc-Rel. Moreover, the transactivation capacity of hybrids containing the RelA RHD was strongly influenced by the nature of the TAD (Figure 3d ). Those containing C-terminal TADs derived from mc-Rel, hc-Rel, or hRelA activated expression of IL6 kB-luc on average 8-22-fold more efficiently than those harboring the v-Rel TAD. This agrees with the intrinsic transcriptional activities of the wild-type factors and further underscores differences in the transactivation capacity of their divergent TADs.
When assayed for malignant cell transformation in the context of primary lymphoid cells, hybrid proteins containing the TAD of RelA fused to the RHDs of vRel, mouse c-Rel, or human c-Rel invariably failed to transform cells (Figure 4a ). In fact, these fusions abolished the transforming potentials of v-Rel, mouse c-Rel and human c-Rel. This was in contrast to the vRel and mouse c-Rel controls that efficiently formed colonies. Importantly, reciprocal fusion of the v-Rel TAD to the RHD of human RelA was sufficient to convert RelA into a potent transforming factor that led to abundant colony formation in soft agar. This was in sharp contrast with the failure of hRelA to transform cells (Figures 1a and 4a) . Similar results were observed with an mRelA/v-Rel hybrid (data not shown). Individual colonies of cells transformed by hRelA/v-Rel could be expanded in liquid culture, although they exhibited a more limited lifespan of approximately 3-5 months in liquid culture compared to those transformed by v-Rel or mammalian c-Rel proteins that grew indefinitely (41 year). Western-blot analysis using antibodies specific for the N-terminus of hRelA or the C-terminus of v-Rel verified expression of the hRelA/v-Rel hybrid in independently transformed hRelA/v-Rel spleen cell clones (Figure 4b ). It is also noteworthy that hRelA/vRel-transformed spleen cells induced lethal tumors within 2 weeks of inoculation in two out of six chickens analysed (hRelA/v-Rel; Figure 2 ). Moreover, all animals that succumbed displayed characteristic tumor nodules Altogether, these data demonstrate that substitution of the v-Rel TAD for that of RelA can convert human RelA into an oncogenic factor in lymphocytes both in vitro and in vivo.
Transactivation domains of human and mouse c-Rel differ in their oncogenic capacity
The mouse and human c-rel genes share 91% aminoacid identity in their N-terminal RHDs and are 59% identical in their C-terminal regions. To investigate the underlying cause for their significantly different oncogenic capacities, we compared the transforming activity of hybrid proteins generated between them (Figure 5a ). In agreement with the results of Figures 1a and 4a , mouse c-Rel was highly effective in transforming primary lymphoid cells, whereas human c-Rel gave rise significantly to fewer colonies in soft agar (Figure 5b) . Fusion of the mouse c-Rel TAD to the RHD of human c-Rel significantly increased colony formation compared to wild-type human c-Rel. Conversely, the transforming activity of mouse c-Rel was reduced when the human c-Rel TAD was used to substitute its own TAD. This suggested that the TADs of mammalian c-Rel proteins are not functionally equivalent for oncogenesis.
Fusion of the mouse c-Rel TAD to the RHD of human RelA induced cell transformation albeit at a much-reduced efficiency compared to the v-Rel TAD (compare hRelA/mc-Rel with hRelA/v-Rel; Figure 5b ). Fusion of the human c-Rel TAD to the RelA RHD also gave rise to rare cell transformation, at a low efficiency in the range of those observed with wild-type human cRel (compare hRelA/hc-Rel with hc-Rel). In contrast to the transformed cells that arose with hRelA/mc-Rel, a single colony of cells transformed by hRelA/hc-Rel could be propagated in liquid culture (data not shown). In all cases, immunoblotting confirmed efficient expression of the expected hybrid proteins in individual (Figures 5c and 4b ). In conjunction with the results described above, these findings emphasize the notion that the transactivation domains of individual c-Rel and RelA factors are not functionally equivalent and that critical determinants for their different oncogenicity reside within their divergent C-terminal domains.
Differential association with IkBa is not the primary cause for the different oncogenic potentials of the mouse and human c-Rel proteins
IkBa functionally inactivates NF-kB by promoting accumulation of inactive IkB/NF-kB complexes in the cytoplasm and interfering with nuclear NF-kB DNA binding. Consistent with the concept that malignant cell transformation by Rel/NF-kB is dependent on DNA binding and transcriptional activation, v-Rel and its homolog chicken c-Rel induce IkBa gene expression with different kinetics and v-Rel is more resistant to the inhibitory effects of IkBa than c-Rel (Diehl et al., 1993; Hrdlickova et al., 1995; Rottjakob et al., 1996; Carrasco et al., 1997) . Two amino-acid differences in the vicinity of the nuclear localization sequence (NLS) of the chicken c-Rel protein are responsible for the decreased association of v-Rel with IkBa (Y286S and L302P). Substitution of these residues in c-Rel by those from v-Rel significantly increased the transforming ability of chicken c-Rel, coincident with an increased resistance to the inhibitory effects of IkBa (Sachdev and Hannink, 1998) . We therefore investigated the extent to which differences in endogenous IkBa expression and/or differential association with IkBa might contribute to the different transforming activities of the mouse and human c-Rel proteins. As shown in Figure 5d , the steady-state levels of endogenous IkBa were comparable between spleen cells transformed by mouse c-Rel and those transformed by human c-Rel, suggesting that at least in the case of the IkBa gene the mouse and human c-Rel proteins exhibit a similar capacity to interact with the transcriptional machinery in chicken spleen cells (lanes 1 and 2) . Moreover, little or no difference was observed between endogenous IkBa interaction with the mouse or human c-Rel proteins in coimmunoprecipitation assays, despite their markedly different transforming efficiencies (Figure 5d , lanes 3 and 4; and Figures 1a, 4a and 5b). These findings indicate that although increased resistance to inhibition by IkBa contributes to the enhanced oncogenic activity of v-Rel, differential association with IkBa is not a primary contributing factor to the significantly different oncogenic potentials of mammalian c-Rel proteins. The data rather support a model in which their different transforming activities may derive from properties associated with their more divergent TADs, which may dictate fundamental differences in the repertoire of genes that they regulate and the magnitude of their expression.
v-Rel transactivation domain selectively confers an oncogenic phenotype upon the RHD of RelA but not the RHD of all cellular Rel/NF-kB factors
The successful conversion of hRelA into an efficient transforming factor in the context of the hRelA/v-Rel hybrid raised the possibility that the v-Rel TAD could similarly confer an oncogenic phenotype upon the RHDs of other cellular members of the mammalian Rel/NF-kB family. To investigate this hypothesis, the vRel TAD was fused in-frame to the RHDs of p50/NFkB1, p52/NF-kB2, and RelB and their transforming activities were compared with that of RelA/v-Rel (Figure 6a, b) . Appropriate expression of wild-type and hybrid proteins was verified by Western blot (data not shown). As shown in Figure 6b , none of the mammalian Rel/NF-kB factors could induce colony formation on their own when overexpressed in primary spleen cells, with the exception of mouse c-Rel and human c-Rel. Fusion of the v-Rel TAD to the RHD of human RelA caused cell transformation, in agreement with the data described above. In sharp contrast, fusion of the v-Rel TAD to the RHDs of hp50, hp52, or mRelB invariably failed to transform cells (Figure 6b ). In light of the vastly different transforming abilities of these mammalian RHD/v-Rel hybrids compared with hRelA/ v-Rel and mRelA/v-Rel, it appears that their more distantly related RHDs may fail to show an oncogenic capacity owing to differences in their ability to form particular dimeric complexes and/or to exhibit distinct DNA-binding specificities. In combination with our 
Discussion
There is substantial evidence that constitutive activation and/or amplification of the rel/nf-kb genes is correlated with human hematopoietic and solid tumors. Here, we show that overexpression of human or mouse c-rel alone suffices to transform primary chicken lymphoid cells in stringent soft agar assays, one of the more rigorous indicators of cell transformation. We also demonstrate that these cells could provoke formation of fatal lymphomas in immunocompetent animals, consistent with the nuclear accumulation of c-Rel protein in some human lymphomas that display c-rel gene amplification . These results further expand on recent reports indicating that human c-rel could promote the growth of chicken lymphoid cells in liquid culture assays (Gilmore et al., 2001; Starczynowski et al., 2003) . Combined, these results argue in favor of an active role for c-rel in leukemia/lymphomagenesis, akin to its recently described role in inducing mammary carcinoma in a transgenic mouse model (RomieuMourez et al., 2003) .
Our studies also identified fundamental differences in the oncogenic activities of mammalian c-Rel and Rel/ NF-kB proteins and revealed a determining role for their divergent transactivation domains, as summarized in Table 1 . Although chromosomal aberrations involving the human c-rel, relA, nf-kb1, and nf-kb2 genes have been reported in hematopoietic tumors, c-rel is the most commonly amplified member of this family in hematopoietic cancers (reviewed in Rayet and Ge´linas, 1999; Gilmore et al., 2002) . So far there have been only a relA rather appears to be preferentially involved as part of activated p65/p50 complexes in tumors that display constitutive IKK activity. It is therefore interesting that mouse c-rel was highly oncogenic both in vitro and in vivo, whereas mouse relA was not. Likewise, human c-rel showed a low yet reproducible capacity to induce colony formation in soft agar that led to tumor formation, whereas human relA repeatedly failed to do so. Even in the context of hybrid proteins containing identical RHDs, the transactivation domains of mouse c-rel and human c-rel were more conducive to cell transformation than that of relA (Table 1) . We do not rule out the possibility that relA might be oncogenic under certain conditions or in certain cells that perhaps fails to grow under our assay conditions, or that it requires cooperative interaction with oncogene(s) or inactivation of tumor suppressor pathway(s) to manifest its oncogenic phenotype. Thus, its failure and that of IKKb SS-EE to form colonies in soft agar and to promote cell growth in liquid culture assays might reflect a weak oncogenic potential that is below the threshold sensitivity for detection in these assays. Alternatively, the inability of IKKb SS-EE to transform in these assays may be cell type specific, as c-Rel activation in B cells was reported to be mediated by CK2 and calpain (Schwarz et al., 1996; Miyamoto et al., 1998; Shen et al., 2001) . It is also conceivable that relA activate genes whose function is incompatible with cell transformation. In this regard, it is interesting to note that overexpressing relA decreased the tumorigenicity of breast cancer cells, although c-rel and NF-kB are activated in breast cancer specimens (Nakshatri et al., 1997; Sovak et al., 1997; Cogswell et al., 2000; Kim et al., 2000; Ricca et al., 2001; RomieuMourez et al., 2001) . In addition, an immortalized relAdeficient mouse fibroblast cell line exhibited a weakly transformed phenotype that was reversed upon reintroduction of relA . In conjunction with our results, these observations point to clear differences between the intrinsic oncogenic activities of mammalian c-Rel and RelA factors. Our observation that selection for deletion or point mutation is not an absolute prerequisite for in vitro lymphocyte transformation by mammalian c-rel genes is noteworthy, as evolution of the c-rel protooncogene into the highly tumorigenic v-rel involved C-terminal deletion along with point mutations and insertion (reviewed in Gilmore, 1999) . The recovery of C-terminally truncated c-Rel proteins from rare tumors in chickens had raised the possibility that selection for C-terminal deletion might be a prerequisite for c-rel oncogenicity . Our results analysing individual transformed cell clones indicate that cell transformation 'per se' does not absolutely require alterations in c-rel. Mutations affecting the Cterminal region of c-rel are thus likely to confer increased tumorigenicity in vivo, enhanced capacity to evade the immune system and/or facilitate cell adaptation to growth in in vitro culture and may result from selective pressure. We, indeed, have data indicating occasional selection for C-terminal truncation of the chicken and human c-Rel proteins arising after prolonged periods of in vitro cell culture (B Rayet, Y Fan, and C Ge´linas, unpublished data). While our data indicate that the human c-rel gene can play an active role in the transformation of primary chicken lymphoid cells, the fact that its amplification is frequently accompanied by other chromosomal alterations characteristic of tumor progression suggests that other cytogenetic abnormalities are likely to act in concert with hc-rel in human cancers (Houldsworth et al., 1996; Rao et al., 1998) . This hypothesis is consistent with the late onset of mammary carcinomas that was recently observed in MMTV-c-rel transgenic mice (RomieuMourez et al., 2003) . Our demonstration that the v-Rel or c-Rel TADs could impart a transforming phenotype upon the RelA RHD implies that critical determinants of the intrinsic oncogenic potentials of mammalian c-Rel and RelA proteins reside in their highly divergent transactivation domains. Consistent with this prediction, differences in oncogenic activities were also observed within the realm of c-rel homologs from chicken, mouse, and human origins. In the context of hybrid molecules with identical RHDs (e.g. RelA vs RelA/v-Rel; hc-Rel vs hc-Rel/mcRel), molecules exhibited significantly different transforming potentials depending on the TAD that they harbored (Table 1 ). Coimmunoprecipitation assays indicated that IkBa is not the primary determinant for their different oncogenic potentials, as human and mouse c-Rel showed comparable association with IkBa despite their significantly different transforming activities. This further points to a critical role for defined TADs in promoting efficient cell transformation.
The molecular basis for the distinct contribution of different c-Rel and RelA TADs to lymphocyte transformation has yet to be fully elucidated. Structures are available for the N-terminal RHDs of several Rel/NFkB factors such as c-Rel, RelA, p50/NF-kB1, and p52/ NF-kB2, but information is still lacking on the structure of their C-terminal domains (Ghosh et al., 1995; Muller et al., 1995; Cramer et al., 1997; Chen et al., 1998a, b; Huang et al., 2001) . It is clear that differences in the DNA-binding specificity of individual RHDs will influence the oncogenic potential of Rel/NF-kB proteins. For instance in our assays, the v-Rel TAD conferred an oncogenic phenotype upon the RHD of RelA, but not to the more divergent RHDs of p50, p52, or RelB. However, it remains to be determined whether individual Rel/NF-kB TADs have the capacity to activate a distinct and only partially overlapping subset of genes, as seen with Jun-family members (Claret et al., 1996) . Indeed, a recent study revealed that the transactivation specificity of individual NF-kB family members for endogenous promoters is not solely determined by DNA-protein interactions at the kB DNA site (Hoffmann et al., 2003) . It is thus tempting to speculate that individual Rel TADs perhaps participate in defined protein-protein interactions that play a decisive role in specifying the transcriptional programs that they activate. In this scenario 'transforming' Rel TADs might interact with target-selective cofactors similar to those that increase the target specificity of AP-1, PPARg, and androgen receptor, to induce programs of gene expression that 'nontransforming' TADs may fail to activate efficiently (Claret et al., 1996; Puigserver et al., 1998; Heinlein et al., 1999) .
A proper level of gene activation within a suitable range also appears to be an important requirement for cell transformation. The RelA TAD is generally stronger than that of c-Rel on most NF-kB DNA sites, and in turn both are stronger than that of v-Rel. Yet vRel is more highly oncogenic than c-Rel in primary chicken lymphoid cells, and c-Rel is more transforming than RelA. However, it is important to note that v-Rel is better than c-Rel in activating c-jun transcription, which has been implicated as an important target for v-Relmediated transformation (Fujii et al., 1996; Kralova et al., 1998) . Consistent with these findings, enhanced v-Rel transcriptional activity often coincides with improved transforming potential. For instance, both a v-Rel TAD mutant and a v-Rel RHD fusion to the second acidic TAD of cc-Rel showed enhanced transactivation ability compared with v-Rel and a corresponding increase in transforming potential (Rayet et al., 2003; Y Fan and C Ge´linas, in preparation) . Yet, transactivation beyond a certain level seems to be detrimental for cell transformation, as fusion of the vRel or c-Rel RHDs to the more potent TADs of tumor suppressor p53 or Herpes Simplex virus VP16 failed to transform cells (Starczynowski et al., 2003; N Gupta, Y Fan, and C Ge´linas, unpublished data) . The fact that a truncated and attenuated VP16DN TAD allowed transformed cell growth in liquid culture assays supports this hypothesis (Starczynowski et al., 2003) . Consequently, it is conceivable that significantly more potent TADs such as those of RelA, p53, or VP16 perhaps activate gene expression to a level that is incompatible with cell transformation.
While further work will be needed to fully elucidate the mechanisms responsible for the distinct oncogenic potentials of Rel/NF-kB factors, our studies highlight an important role for the Rel TADs in malignant lymphoid cell transformation both in vitro and in vivo. These findings underscore the notion that the ability of individual NF-kB members to drive distinct programs of gene expression may significantly impact their oncogenic phenotype. It will therefore be interesting to see if the different transforming activities of c-Rel and RelA reflect meaningful differences in the genes that they activate, including those important for cell proliferation and the suppression of apoptosis (reviewed in Sonenshein, 1997; Pahl, 1999; Gilmore et al., 2002; Karin et al., 2002; Orlowski and Baldwin, 2002; Kucharczak et al., in press) . It should also be informative to see how their gene expression profiles compare to those of human lymphomas in which NF-kB is implicated (Alizadeh et al., 2000; Hinz et al., 2002; Shipp et al., 2002; Garcia et al., 2003) . Together, these analyses may help to identify critical targets for Rel/NF-kB-mediated oncogenesis.
Materials and methods
Plasmids and cell lines
Viral and cellular rel/nf-kb genes were expressed in vivo under the control of the cytomegalovirus (CMV) immediate-early promoter of pJDCMV19SV for transactivation assays, or from the long terminal repeat (LTR) promoter of spleen necrosis virus (SNV)-derived retroviral vector pJD214 for assays of spleen cell transformation (Dougherty and Temin, 1986; Dougherty et al., 1989) . Plasmid SW253 encodes a replication-competent RevA helper virus (Watanabe and Temin, 1983) . pIL6kBLuc was derived from pIL6kBCAT and expressed a luciferase reporter gene under the control of three NF-kB DNA-binding motifs derived from the IL-6 promoter (Suh et al., 2002) . The renilla luciferase plasmid pRL-null was used as an internal control (Promega Corp., Madison, WI, USA). The coding regions of the human c-rel (hc-Rel; amino acids 1-619), mouse c-rel (mc-Rel; 1-587), human relA (hRelA; 1-551), mouse relA (mRelA; 1-554), human p50/nf-kb1 (hp50; 1-433), human p52/nf-kb2 (hp52; 1-405), and mouse relB (mRelB; 1-558) genes were amplified by PCR using Pfu Native DNA polymerase (Stratagene) and cloned by blunt-end ligation into pJDCMV19SV or pJD214 vectors previously linearized with XbaI. The chicken c-rel and human c-rel cDNAs were gifts of T Gilmore (Boston University, MA, USA) and NR Rice (ABL-NCI, Frederick, MD, USA). The mouse c-rel (mc-rel) cDNA used in this study was a gift from S Tilghman (Princeton University, NJ, USA). cDNAs for mouse and human relA, mouse relB, human p50/ nf-kb1, and human p52/nf-kb2 were gifts from R Sen (Brandeis University, MA, USA), G Sonenshein (Boston University, MA, USA), C Paya (Mayo Clinic, NY, USA), U Siebenlist (NIH-Bethesda, MD, USA) and A Rabson (CABM, NJ, USA). Hybrid Rel/NF-kB proteins with exchanged N-and C-terminal halves were generated by overlap-anneal PCR. All constructs were verified by automated sequencing (NJMS Molecular Resource Facility, Newark, NJ, USA). pcDNA3.1 Flag-hIKKb was a gift from WC Greene (Gladstone Institute, UCSF, CA, USA). The Flag-hIKKb SS-EE mutant was generated with the QuickChange mutagenesis kit (Stratagene) by L Edelstein (CABM, NJ, USA). The Flag-IKKb SS-EE insert was isolated from pcDNA3.1 with XbaI and HindIII. After filling the ends with Klenow polymerase, XbaI linkers were added (New England Biologicals) and the insert was subcloned into the XbaI site of pJD214.
Human Tera-2 cells (embryonic carcinoma; HTB-106, American Type Culture Collection, Manassas, VA, USA) were maintained in McCoy's 5A medium supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 mg/ml; Gibco Life Technology, Grand Island, NY, USA). Human 293T cells (Adenovirus-transformed human embryonal kidney cells expressing the SV40 large T antigen) were maintained in DMEM medium supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (100 mg/ml). Transformed chicken spleen cells were cultured in DMEM containing 20% FBS, 1% chicken serum, and antibiotics. Cells were maintained at 371C in a 5% CO 2 incubator, with the exception of chicken spleen cells, which were maintained at 40.51C and 7.5% CO 2 .
Transformation of primary chicken spleen cells and in vivo tumorigenicity assays
Primary chicken spleen cells from 3-week-old chickens (Charles River SPAFAS, North Franklin, CT, USA) were electrophorated with SNV-derived retroviral vector DNAs (20 mg) and the SW253 Rev-A helper virus DNA (10 mg) essentially as described (Mosialos et al., 1991) . The efficiency of spleen cell transformation was significantly improved by carefully screening the serum lots used in these assays (Rayet et al., 2003) . Cells were maintained in liquid culture for 3 days, followed by transfer into soft agar. Colonies of transformed lymphoid cells were scored 10-14 days later. Individual colonies were picked and expanded in liquid culture. The in vivo tumorigenicity of v-Rel and cellular Rel/ NF-kB proteins was assayed by intraperitoneal injection of 5-day-old chickens with transformed spleen cells (2 Â 10 6 ). Animals were monitored twice daily. All animals that died had tumor nodules affecting their spleen and liver visible upon autopsy.
Immunoblotting and coimmunoprecipitation assays
Transiently transfected 293T cells or transformed chicken spleen cells were lysed in EBC buffer (50 mM Tris pH 8.0, 120 mM NaCl, 0.5% NP-40, 10% glycerol) in the presence of protease inhibitor cocktail (Boehringer, Manheim, Germany). Total protein concentration was determined by the method of Bradford (1976) . Proteins were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membranes (Schleicher and Schuell, Keene, NH, USA). Secondary antibody detection was performed by enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Antibodies used for these analyses included rabbit polyclonal antibodies specific for the C-terminus of v-Rel (#1691; or the N-terminus of v-Rel (#1967; (Xu et al., 1993) . Antibodies specific for the NLS of p50 (#1613), the C-terminus of mouse c-Rel (#1266), the mid-region of human c-Rel (#1136), the C-terminus of human c-Rel (#265), the Nterminus of human RelA (#1207), the C-terminus of human RelA (#1226), or chicken IkBa (#1275) were generous gifts from NR Rice and MK Ernst (NCI, Frederick MD, USA) and HR Bose (University of Texas-Austin, TX, USA). Commercially available antibodies were polyclonal anti-human c-Rel N-terminus (sc-272) or monoclonal anti-human c-Rel Nterminus antibody (sc-6955) (Santa Cruz Biotechnology, CA, USA), polyclonal anti-human RelA C-terminus (100-4165; Rockland Immunochemicals, Gilbertsville, PA, USA), and anti-actin (Sigma).
For coimmunoprecipitation assays, whole-cell extracts from transformed spleen cell clones were lysed in EBC buffer containing protease inhibitor cocktail (Boehringer, Manheim, Germany) and quantitated by the method of Bradford. Equal amounts of total protein (400 mg) were immunoprecipitated with an antibody against endogenous chicken IkBa (# 1275) and protein A-sepharose (Pharmacia). Samples were washed extensively with EBC buffer supplemented with protease inhibitor cocktail, resolved by SDS-PAGE and transferred to nitrocellulose membranes for Western-blot analysis.
RT-PCR analysis of proviral DNA Total RNA was extracted using RNAzol B (TEL-TEST, Inc, Friendswood, TX, USA). RT-PCR was performed with total RNA (500 ng) using the Titan One Tube RT-PCR System kit (Boehringer, Mannheim, Germany). The following primer pairs were used for RT-PCR: mc-rel#1 GGCTGACTGACT CACTGACTGAC, mc-rel#2 ATATACTTATTTAAGTCCT ACAAC, hc-rel#1 GCTCTAGAGAGCCATGGCCTCC, hc-rel#2 GCTCTAGAGCAAGTTATACTTG, v-relS7 GGG GCCGGTCTAGAAAGCTCCTGAC, v-relS10 CCCCGGC CTCACGAACGATACCCGAC, cc-relS1 TCGGTACCCG GGCAGTCCGCGGCGG, cc-relS6 CTCTAGAGGATCCC CCGGCTCAATG. PCR products were separated on 1% agarose gels and analysed by automated sequencing (NJMS Molecular Resource Facility, Newark, NJ, USA).
Transient transfections and luciferase assays
Human Tera-2 cells (1.2 Â 10 5 ) were seeded in 12-well dishes in 1.6 ml of complete medium. On the following day, cells were cotransfected with CMV vectors encoding Rel, RelA, or hybrid proteins (0.8 mg), IL6kBLuc (0.4 mg) and pRLnull (0.0125 mg) DNAs using Mirus Trans IT-LT1 (2.5 ml, PanVera Corporation, Madison, WI, USA). Cells were harvested at 48 h after transfection for dual-luciferase assays (Promega Corp., Madison, WI, USA). Human 293T cells (2.5 Â 10 5 ) were seeded in six-well dishes in 2 ml of complete medium. On the following day, cells were transfected with SNV-derived retroviral vector DNAs encoding Rel, RelA, or hybrid proteins (3 mg) using calcium phosphate (Chen and Okayama, 1987) . Cells were harvested at 48 h post-transfection. Whole-cell extracts were prepared for analysis of protein expression. Nuclear extracts were prepared for DNAbinding assays.
DNA-binding assays
Nuclear extracts from transformed chicken spleen cells or transiently transfected 293T cells were prepared as described (Schreiber et al., 1989) . Briefly, cells were washed several times in Tris-buffered saline (TBS) and resuspended in buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 1 Â protease inhibitor cocktail (Boehringer-Mannheim, Germany). Cells were incubated on ice for 15 min before addition of NP-40 to a final concentration of 0.625%. After centrifugation, nuclei-containing pellets were resuspended in buffer C (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF and 1 Â protease inhibitor cocktail), vortexed vigorously and rotated for 15 min at 41C. After centrifugation, supernatants containing nuclear extracts were collected. Nuclear extracts (3 mg) were incubated with a 32 P-labeled double-stranded IL-6-kB oligonucleotide probe (4 Â 10 4 cpm) in 10 mM Tris, pH 7.5, 50 mM NaCl, 7.5 mM MgCl 2 , 1 mM EDTA, 5% glycerol, 5% sucrose, 0.1% NP-40, 0.5 mg poly dIdC, 5 mM DTT, 10 mg bovine serum albumin (BSA). DNA/ protein complexes were analysed on 5% native polyacrylamide gels. Where indicated, antibodies were added to binding reactions to supershift the complexes.
